实体瘤全身辅助治疗降阶梯试验的安全与良好设计路线图
本文由BIG与NABCG成员基于多项辅助治疗降阶梯试验的经验与患者焦点小组讨论,提出未来降阶梯试验设计与实施的路线图。内容涵盖非劣效性设计、终点选择及患者视角优先等共识考虑,旨在平衡疗效与毒性及经济负担。
要点
- 降阶梯试验需吸取既往设计缺陷与入组不佳的教训。
- 非劣效性设计与终点选择是降阶梯试验的关键考量。
- 患者视角应纳入降阶梯试验的优先考量。
核心结论
- 改善未来降阶梯试验的设计与实施需吸取既往试验教训并重视患者真正关切。
研究设计与样本
- BIG与NABCG成员综述不同癌种辅助试验并结合焦点小组讨论形成共识。
主要发现
- 部分降阶梯试验因入组差或设计缺陷导致结果矛盾,仅少数提供明确答案。
关键数值与推荐
- 共识提出非劣效性试验设计、终点选择及患者视角优先等考量。
临床怎么用
- 未来设计实体瘤辅助治疗降阶梯试验时应参考该路线图。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
An important challenge in the field of cancer is finding the balance between delivering effective treatments and avoiding adverse effects and financial toxicity caused by innovative, yet expensive, drugs. To address this, several treatment de-escalation trials have been conducted, but only a few of these have provided clear answers. A few trials had poor accrual or had design flaws that led to conflicting results. Members of the Breast International Group (BIG) and North American Breast Cancer Group (NABCG) believe the way forward is to understand the lessons from these trials and listen more carefully to what truly matters to our patients. We reviewed several adjuvant trials of different cancer types and developed a road map for improving the design and implementation of future de-escalation trials. The road map incorporates patients' insights obtained through focused group discussions across the BIG-NABCG networks. Considerations for the development of de-escalation trials for systemic adjuvant treatment, including noninferiority trial design, choice of end points, and prioritization of a patient's perspectives, are presented in this consensus article.
引用
- Piccart MJ, Hilbers FS, Bliss JM, et al. Road Map to Safe and Well-Designed De-escalation Trials of Systemic Adjuvant Therapy for Solid Tumors. J Clin Oncol. 2020. PMID: 33052755. doi:10.1200/JCO.20.01382
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。